KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2016 - 2026)

Biomarin Pharmaceutical has reported Change in Accured Expenses over the past 18 years, most recently at $3.1 million for Q1 2026.

  • For the quarter ending Q1 2026, Change in Accured Expenses rose 49.83% year-over-year to $3.1 million, compared with a TTM value of $67.2 million through Mar 2026, up 300.62%, and an annual FY2025 reading of $66.1 million, up 305.14% over the prior year.
  • Change in Accured Expenses came in at $3.1 million for Q1 2026, down from $44.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $76.6 million in Q2 2022 to a low of -$78.1 million in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was $3.3 million (2024), compared with a mean of $7.0 million.
  • The sharpest move saw Change in Accured Expenses soared 2452.39% in 2023, then plummeted 559.03% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $62.3 million in 2022, then tumbled by 85.14% to $9.3 million in 2023, then plummeted by 559.03% to -$42.5 million in 2024, then soared by 204.18% to $44.2 million in 2025, then plummeted by 92.99% to $3.1 million in 2026.
  • Per Business Quant, the three most recent readings for BMRN's Change in Accured Expenses are $3.1 million (Q1 2026), $44.2 million (Q4 2025), and $18.8 million (Q3 2025).